Literature DB >> 23425651

Vitamin D-binding protein levels in female patients with primary hyperparathyroidism.

Xiangbing Wang1, Sue A Shapses, Sun Wei, Deeptha Sukumar, Jaya Ghosh.   

Abstract

OBJECTIVE: To determine whether low levels of vitamin D-binding protein (DBP) are related to 25-hydroxyvitamin D (25[OH]D) deficiency in female patients with primary hyperparathyroidism (PHPT).
METHODS: Twenty-five female patients with PHPT (serum calcium level >10.2 mg/dL and intact parathyroid hormone (iPTH) level >66 pg/mL) and 25 healthy age- and body mass index-matched female control subjects were xaminod. Serum calcium and iPTH levels were determined by commercial laboratories. Levels of 25(OH)D and 1,25-dihydroxyvitamin D (1,25[OH]₂D) were determined by radioimmunoassay, and DBP level was determined by enzyme-linked immunosorbent assay.
RESULTS: Serum iPTH and calcium levels were higher in PHPT patients than control subjects (P<.001). Levels of 25(OH)D, albumin, and DBP were lower in the serum of PHPT patients than control subjects (P<.01). There were no significant differences in 1,25(OH)₂D and free 25(OH)D levels between PHPT patients and control subjects. DBP level was inversely correlated with calcium (r = -0.47; P<.01) and iPTH (r = -0.31; P<.05) levels. The 25(OH)D level correlated positively with both DBP (r = 0.28; P<.05) and albumin (r = 0.44; P<.05) levels.
CONCLUSION: Both serum 25(OH)D and DBP levels were lower in female patients with PHPT compared with control subjects. We suggest that a low DBP level contributes to the low 25(OH)D level observed in female PHPT patients. The etiology of the decrease in DBP and its relationship to calcium, 25(OH)D, and PTH levels require further investigation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23425651     DOI: 10.4158/EP12371.OR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  7 in total

1.  Free vitamin D does not vary through the follicular phase of the menstrual cycle.

Authors:  J M Franasiak; X Wang; T A Molinaro; K Green; W Sun; M D Werner; C R Juneau; R T Scott
Journal:  Endocrine       Date:  2016-04-06       Impact factor: 3.633

2.  Vitamin D status in primary hyperparathyroidism: effect of genetic background.

Authors:  Claudia Battista; Vito Guarnieri; Vincenzo Carnevale; Filomena Baorda; Mauro Pileri; Maria Garrubba; Antonio S Salcuni; Iacopo Chiodini; Salvatore Minisola; Elisabetta Romagnoli; Cristina Eller-Vainicher; Stefano A Santini; Salvatore Parisi; Vincenzo Frusciante; Andrea Fontana; Massimiliano Copetti; Geoffrey N Hendy; Alfredo Scillitani; David E C Cole
Journal:  Endocrine       Date:  2016-05-06       Impact factor: 3.633

3.  VITAMIN D-BINDING PROTEIN IN HEALTHY PRE- AND POSTMENOPAUSAL WOMEN: RELATIONSHIP WITH ESTRADIOL CONCENTRATIONS.

Authors:  L Claudia Pop; Sue A Shapses; Brian Chang; Wei Sun; Xiangbing Wang
Journal:  Endocr Pract       Date:  2015-06-29       Impact factor: 3.443

Review 4.  VITAMIN D BINDING PROTEIN AND 25-HYDROXYVITAMIN D LEVELS: EMERGING CLINICAL APPLICATIONS.

Authors:  Navinder K Jassil; Anupa Sharma; Daniel Bikle; Xiangbing Wang
Journal:  Endocr Pract       Date:  2017-01-17       Impact factor: 3.443

Review 5.  Vitamin D Binding Protein Impact on 25-Hydroxyvitamin D Levels under Different Physiologic and Pathologic Conditions.

Authors:  Pegah Yousefzadeh; Sue A Shapses; Xiangbing Wang
Journal:  Int J Endocrinol       Date:  2014-04-28       Impact factor: 3.257

6.  Editorial: Vitamin D Binding Protein, Total and Free Vitamin D Levels in Different Physiological and Pathophysiological Conditions.

Authors:  Zhongjian Xie; Xiangbing Wang; Daniel D Bikle
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-11       Impact factor: 5.555

Review 7.  Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all?

Authors:  John P Bilezikian; Anna Maria Formenti; Robert A Adler; Neil Binkley; Roger Bouillon; Marise Lazaretti-Castro; Claudio Marcocci; Nicola Napoli; Rene Rizzoli; Andrea Giustina
Journal:  Rev Endocr Metab Disord       Date:  2021-12-23       Impact factor: 6.514

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.